{"count":4,"next":null,"previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/7adf577e-96b6-43e0-a325-ab7672eb69a5/","filing_uuid":"7adf577e-96b6-43e0-a325-ab7672eb69a5","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7adf577e-96b6-43e0-a325-ab7672eb69a5/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul Miller","dt_posted":"2026-07-20T15:43:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1730 Pennsylvania Avenue NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401103834,"url":"https://lda.gov/api/v1/registrants/401103834/","house_registrant_id":null,"name":"THEGROUP DC, LLC","description":"​Consulting and lobbying services.","address_1":"1730 Pennsylvania Avenue NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL L. MILLER III","contact_telephone":"+1 202-386-7282","dt_updated":"2026-07-20T16:34:02.921317-04:00"},"client":{"id":57261,"url":"https://lda.gov/api/v1/clients/57261/","client_id":57261,"name":"ASTELLAS PHARMA US, INC","general_description":"Pharmaceutical research and manufacturing company.","client_government_entity":null,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-09-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7adf577e-96b6-43e0-a325-ab7672eb69a5/","filing_uuid":"7adf577e-96b6-43e0-a325-ab7672eb69a5","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/7adf577e-96b6-43e0-a325-ab7672eb69a5/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul Miller","dt_posted":"2026-07-20T15:43:55-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1730 Pennsylvania Avenue NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401103834,"url":"https://lda.gov/api/v1/registrants/401103834/","house_registrant_id":null,"name":"THEGROUP DC, LLC","description":"​Consulting and lobbying services.","address_1":"1730 Pennsylvania Avenue NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL L. MILLER III","contact_telephone":"+1 202-386-7282","dt_updated":"2026-07-20T16:34:02.921317-04:00"},"client":{"id":57261,"url":"https://lda.gov/api/v1/clients/57261/","client_id":57261,"name":"ASTELLAS PHARMA US, INC","general_description":"Pharmaceutical research and manufacturing company.","client_government_entity":null,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-09-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a5e9b2b4-d1d7-488d-9a27-3c75ac14aa81/","filing_uuid":"a5e9b2b4-d1d7-488d-9a27-3c75ac14aa81","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/a5e9b2b4-d1d7-488d-9a27-3c75ac14aa81/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul Miller","dt_posted":"2026-10-20T18:45:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1730 Pennsylvania Avenue NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401103834,"url":"https://lda.gov/api/v1/registrants/401103834/","house_registrant_id":null,"name":"THEGROUP DC, LLC","description":"​Consulting and lobbying services.","address_1":"1730 Pennsylvania Avenue NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL L. MILLER III","contact_telephone":"+1 202-386-7282","dt_updated":"2026-07-20T16:34:02.921317-04:00"},"client":{"id":57261,"url":"https://lda.gov/api/v1/clients/57261/","client_id":57261,"name":"ASTELLAS PHARMA US, INC","general_description":"Pharmaceutical research and manufacturing company.","client_government_entity":null,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-09-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a5e9b2b4-d1d7-488d-9a27-3c75ac14aa81/","filing_uuid":"a5e9b2b4-d1d7-488d-9a27-3c75ac14aa81","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/a5e9b2b4-d1d7-488d-9a27-3c75ac14aa81/print/","filing_document_content_type":"text/html","income":"70000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Paul Miller","dt_posted":"2026-10-20T18:45:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1730 Pennsylvania Avenue NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":401103834,"url":"https://lda.gov/api/v1/registrants/401103834/","house_registrant_id":null,"name":"THEGROUP DC, LLC","description":"​Consulting and lobbying services.","address_1":"1730 Pennsylvania Avenue NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL L. MILLER III","contact_telephone":"+1 202-386-7282","dt_updated":"2026-07-20T16:34:02.921317-04:00"},"client":{"id":57261,"url":"https://lda.gov/api/v1/clients/57261/","client_id":57261,"name":"ASTELLAS PHARMA US, INC","general_description":"Pharmaceutical research and manufacturing company.","client_government_entity":null,"client_self_select":false,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-09-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"H.Res.1090, Expressing support for the designation of February 2026 as \"Low Vision and Vision Impairment Awareness Month\" Issues related to the treatment of menopause and womens health at mid-life.","foreign_entity_issues":"Astellas Pharma, Inc., identified on Form LD-1, has interests in the issues lobbied.","lobbyists":[{"lobbyist":{"id":62883,"prefix":null,"prefix_display":null,"first_name":"DARREL","nickname":null,"middle_name":null,"last_name":"THOMPSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141008,"prefix":null,"prefix_display":null,"first_name":"ESTEFANIA","nickname":null,"middle_name":null,"last_name":"RODRIGUEZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}